BioAlliance Pharma Obtains European Approval for Loramyc Tablet Embossing and Extension of Its Shelf Life to 36 Months

13-Jul-2009 - France

BioAlliance Pharma SA announced Europe-wide approval for embossing its Loramyc® mucoadhesive buccal tablet, developed for the treatment of oropharyngeal candidiasis.

The embossing process has thus been approved under the Mutual Recognition Procedure; it was first required for the US market, where BioAlliance Pharma submitted a new drug application for Loramyc® to the Food and Drug Administration (FDA) in June 2009. BioAlliance Pharma will be able to harmonize Loramyc® production within those two key markets.

BioAlliance Pharma also received European approval for extension of Loramyc®'s shelf life from 18 to 36 months.

These two key industrial parameters are complementary assets for Loramyc® and will help optimizing manufacturing, storage and distribution costs.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance